Skip to content

Science
Investor
About
Learn
Contact

Science
Investor
About
Learn
Contact

Investor Alerts

Investor

News Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Year Keywords

Advanced Search

Search

Search Headlines Only

From

To

Asset Types

Photos Video Audio Documents Events Standard

Sep 24, 2020

InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
Sep 22, 2020

InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing
Sep 8, 2020

InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update
Sep 2, 2020

InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020
Jul 7, 2020

InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755
Jun 30, 2020

InMed Announces Completion of Share Consolidation
Jun 24, 2020

InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System
Jun 19, 2020

InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation
May 27, 2020

InMed Releases CBN Preclinical Results in Glaucoma
May 19, 2020

InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family
May 14, 2020

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
May 12, 2020

InMed Files PCT Patent Application for Neuroprotection in Glaucoma
May 8, 2020

Notice of Telephone Scam Impersonating InMed
May 8, 2020

InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020
May 7, 2020

InMed to Present at Canaccord Genuity's 4th Annual Cannabis Conference
May 5, 2020

InMed and Almac Group Developing Improved Cannabinoid Production Methods
Apr 30, 2020

InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755
Apr 1, 2020

InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
Mar 24, 2020

InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial
Mar 20, 2020

InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak
Mar 10, 2020

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
Feb 14, 2020

InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
Feb 7, 2020

InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Results and Business Update on February 14, 2020
Jan 21, 2020

InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview
Jan 20, 2020

InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials

Show 5 10 25 50 100 per page

«
1
2
3
4
5
6
»

Investor Alerts

Sign up for investor alerts!

Information Request

Send us a request for information

#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Science

INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
INM-405 for Orofacial Pain
IntegraSyn™ Cannabinoid Manufacturing
InMed’s Research of Rare Cannabinoids

Investor

News Releases
Latest Presentation
Letter to Shareholders
SEDAR^® Filings
Financial Reports

About

Management
Board of Directors
Scientific Advisory Board
Corporate Governance
Careers
Frequently Asked Questions

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2020 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On: